

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct: +41 22 791 1318 Fax direct: +41 22 791 4730

E-mail: pals@who.int

In reply please

Your reference:

refer to: SAV/NC/2018

Ms Tea Jikia

State Regulation Agency of Medical Activities Ministry of Labour, Health and Social affairs

144, Ak. Tsereteli ave TBILISI 119

Georgia

17 April 2018

Dear Ms Jikia,

Forty-first Annual Meeting of Representatives of National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring 5 to 8 November 2018, Geneva, Switzerland

It is with great pleasure that I write to inform you that the Swiss Agency for Therapeutic Products (Swissmedic), Switzerland, has kindly offered to host our Forty-first Annual Meeting. As you are aware, these meetings are an important forum for members of National Pharmacovigilance (PV) Centres to meet and discuss topical matters of high significance in a collegial environment. The 2018 meeting will be held in Geneva, Switzerland, from 5 to 8 November with commemorative events to celebrate the 50th anniversary of the WHO Programme for International Drug Monitoring (PIDM).

I am sending this invitation to you as our registered contact person for PV in your country. We welcome a maximum of 5 delegates from each country. I would be grateful if you could forward the name(s) of delegate(s) from your country, by 18 May 2018 to megiaslastral@who.int

I kindly remind you that all expenses for attending this meeting will, as usual, have to be met by the participants. However, under special circumstances we could consider supporting the cost for one delegate from your country, on a first-come-first basis.

All meeting details will be available through a dedicated meeting website with a direct line for registration. These details will be communicated by email upon receiving confirmation of participation and nominations. A list of topics proposed by countries is attached for your reference.

I look forward to hearing from you.

Yours sincerely,

Dr Shanthi Pal

Group Lead, Medicines Safety

Safety & Vigilance

Shanler Pal

ENCL: 1